MedTrace Logo

Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using GLP-1 RA Medications for Weight Loss

NCT07611552 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2026-05-28

No results posted yet for this study

Summary

The goal of this double-blind randomized placebo-controlled supplement study is to investigate if the supplement of inulin (prebiotics, 10g/day) has beneficial effects on cardiometabolic risk factors in overweight or obese individuals receiving GLP-1 RA medications for weight loss.

Conditions

  • Obesity & Overweight

Interventions

DIETARY_SUPPLEMENT

inulin (prebiotics)

The intervention dose is 10g/day. The intervention will last for 4 months.

DIETARY_SUPPLEMENT

Placebo Comparator: maltodextrin

The dose is 10g/day for 4 months.

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • An Pan · Huazhong University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07611552 on ClinicalTrials.gov